Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.

Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. Panminerva Med. 2020 Sep 21;: Authors: Romano A, Santoro M, Conticello C, Siragusa S, Di Raimondo F, Martinelli G, Cerchione C Abstract Multiple myeloma (MM) is a hematological malignancy due to uncontrolled proliferation of neoplastic plasma cells in the bone marrow, associated to chromosomal instability and cytogenetic abnormalities, which could have an impact on prognosis. Response to treatment and survival of newly diagnosed myeloma patients is heterogeneous, with median overall survival ranging from two to more than ten years, due to clinical and biological factors. To warrant long-term control of disease, several strategies have been proposed in the last years, including short-term high-dose of treatment, named as consolidation, before maintenance. This review will discuss the role of consolidation in the current myeloma treatment landscape, and further improvements required to optimize tailored front-line therapy. PMID: 32955184 [PubMed - as supplied by publisher]
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research